CDXS
Price
$2.69
Change
-$0.18 (-6.27%)
Updated
Apr 15, 6:59 PM EST
16 days until earnings call
CYTK
Price
$68.00
Change
-$3.56 (-4.97%)
Updated
Apr 15, 6:59 PM EST
16 days until earnings call
Ad is loading...

Compare predictions CDXS vs CYTK

Header iconCDXS vs CYTK Comparison
Open Charts CDXS vs CYTKBanner chart's image
Codexis
Price$2.69
Change-$0.18 (-6.27%)
Volume$334.53K
CapitalizationN/A
Cytokinetics
Price$68.00
Change-$3.56 (-4.97%)
Volume$812.79K
CapitalizationN/A
View a ticker or compare two or three
CDXS vs CYTK Comparison Chart

Loading...

CDXSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CDXS vs. CYTK commentary
Apr 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and CYTK is a StrongBuy.

COMPARISON
Comparison
Apr 16, 2024
Stock price -- (CDXS: $3.48 vs. CYTK: $73.09)
Brand notoriety: CDXS and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 52% vs. CYTK: 47%
Market capitalization -- CDXS: $245.36M vs. CYTK: $7.53B
CDXS [@Biotechnology] is valued at $245.36M. CYTK’s [@Biotechnology] market capitalization is $7.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $568.84B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 2 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 2 green, 3 red.
According to our system of comparison, CYTK is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 4 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 4 bearish.
  • CYTK’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than CYTK.

Price Growth

CDXS (@Biotechnology) experienced а +1.01% price change this week, while CYTK (@Biotechnology) price change was +6.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.71%. For the same industry, the average monthly price growth was +6.49%, and the average quarterly price growth was +103.81%.

Reported Earning Dates

CDXS is expected to report earnings on May 02, 2024.

CYTK is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+4.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CDXS with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYTK($7.53B) has a higher market cap than CDXS($245M). CDXS YTD gains are higher at: 14.262 vs. CYTK (-12.457). CDXS has higher annual earnings (EBITDA): -44.88M vs. CYTK (-456.68M). CYTK has more cash in the bank: 615M vs. CDXS (65.1M). CDXS has less debt than CYTK: CDXS (16M) vs CYTK (756M). CDXS has higher revenues than CYTK: CDXS (70.1M) vs CYTK (7.53M).
CDXSCYTKCDXS / CYTK
Capitalization245M7.53B3%
EBITDA-44.88M-456.68M10%
Gain YTD14.262-12.457-114%
P/E RatioN/AN/A-
Revenue70.1M7.53M931%
Total Cash65.1M615M11%
Total Debt16M756M2%
FUNDAMENTALS RATINGS
CDXS vs CYTK: Fundamental Ratings
CDXS
CYTK
OUTLOOK RATING
1..100
920
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
10018
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5337
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (35) in the Chemicals Specialty industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that CDXS’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that CYTK’s stock grew significantly faster than CDXS’s over the last 12 months.

CDXS's SMR Rating (97) in the Chemicals Specialty industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (37) in the Biotechnology industry is in the same range as CDXS (53) in the Chemicals Specialty industry. This means that CYTK’s stock grew similarly to CDXS’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that CYTK’s stock grew significantly faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSCYTK
RSI
ODDS (%)
Bearish Trend 15 days ago
78%
Bullish Trend 15 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 15 days ago
79%
Bearish Trend 15 days ago
83%
Momentum
ODDS (%)
Bullish Trend 15 days ago
85%
Bullish Trend 15 days ago
86%
MACD
ODDS (%)
Bearish Trend 15 days ago
84%
Bullish Trend 15 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 15 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 15 days ago
79%
Bullish Trend 15 days ago
84%
Advances
ODDS (%)
Bullish Trend 26 days ago
80%
Bullish Trend 20 days ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
82%
Bearish Trend 26 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 15 days ago
85%
Bearish Trend 15 days ago
89%
Aroon
ODDS (%)
Bullish Trend 15 days ago
67%
Bearish Trend 15 days ago
79%
View a ticker or compare two or three
Ad is loading...
CDXSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FERGX13.290.04
+0.30%
Fidelity SAI Emerging Markets Index
PFSZX21.60N/A
N/A
PGIM Jennison Financial Services Z
GSPUX39.36N/A
N/A
Goldman Sachs Large Cap Core R6
FAPJX12.34N/A
N/A
Fidelity Advisor Healthy Future A
MLVRX19.99-0.13
-0.65%
MFS Low Volatility Equity R4

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with ABCL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-0.14%
ABCL - CDXS
48%
Loosely correlated
-1.77%
DNLI - CDXS
46%
Loosely correlated
+0.29%
DNA - CDXS
44%
Loosely correlated
-3.45%
RCKT - CDXS
44%
Loosely correlated
-0.78%
AXON - CDXS
43%
Loosely correlated
-0.48%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with TVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then TVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+4.25%
TVTX - CYTK
57%
Loosely correlated
-4.99%
BCAB - CYTK
45%
Loosely correlated
-1.16%
VBIV - CYTK
44%
Loosely correlated
+2.57%
KRON - CYTK
43%
Loosely correlated
+6.15%
IOVA - CYTK
42%
Loosely correlated
-4.25%
More